Shares of T2 Biosystems Inc (NASDAQ:TTOO) have received a consensus rating of “Hold” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $6.54.

Several research analysts have recently weighed in on TTOO shares. ValuEngine upgraded T2 Biosystems from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 13th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of T2 Biosystems in a research note on Friday, November 3rd. Zacks Investment Research upgraded T2 Biosystems from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Wednesday, November 8th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 price objective on shares of T2 Biosystems in a report on Monday, October 30th.

Several institutional investors and hedge funds have recently modified their holdings of TTOO. LMR Partners LLP bought a new stake in shares of T2 Biosystems in the second quarter worth $180,000. Senvest Management LLC grew its holdings in T2 Biosystems by 15.2% during the second quarter. Senvest Management LLC now owns 2,837,946 shares of the medical equipment provider’s stock valued at $9,110,000 after purchasing an additional 373,876 shares during the period. Goldman Sachs Group Inc. grew its holdings in T2 Biosystems by 0.4% during the second quarter. Goldman Sachs Group Inc. now owns 4,270,632 shares of the medical equipment provider’s stock valued at $13,709,000 after purchasing an additional 18,000 shares during the period. Lagoda Investment Management L.P. grew its holdings in T2 Biosystems by 15.4% during the second quarter. Lagoda Investment Management L.P. now owns 1,975,921 shares of the medical equipment provider’s stock valued at $6,343,000 after purchasing an additional 264,337 shares during the period. Finally, Susquehanna International Group LLP grew its holdings in T2 Biosystems by 931.3% during the second quarter. Susquehanna International Group LLP now owns 85,620 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 95,920 shares during the period. 59.77% of the stock is owned by institutional investors.

T2 Biosystems (TTOO) opened at $4.06 on Thursday. T2 Biosystems has a one year low of $2.50 and a one year high of $6.99. The company has a debt-to-equity ratio of 2.25, a current ratio of 5.40 and a quick ratio of 5.28.

T2 Biosystems (NASDAQ:TTOO) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.04. T2 Biosystems had a negative return on equity of 244.82% and a negative net margin of 1,497.70%. The firm had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $1.10 million. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. equities research analysts predict that T2 Biosystems will post -1.85 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “T2 Biosystems Inc (TTOO) Given Consensus Recommendation of “Hold” by Analysts” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/14/t2-biosystems-inc-ttoo-given-consensus-recommendation-of-hold-by-analysts.html.

About T2 Biosystems

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Analyst Recommendations for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.